The Centers for Medicare & Medicaid Services yesterday announced Medicare coverage for monoclonal antibody therapies, with no beneficiary cost-sharing for the duration of the COVID-19 public health emergency. CMS said the coverage will apply to bamlanivimab, the Lilly therapeutic that earned an emergency use authorization earlier this week. Additionally, the agency said it anticipates that bamlanivimab and other, similar therapies will initially be given by drug makers to health care providers at no charge; as such, the Medicare program will not pay for monoclonal antibody products that providers receive for free.

Medicare will, however, reimburse for these therapies’ infusion. Once health care providers begin purchasing monoclonal antibody products, CMS anticipates setting the payment rate in the same manner it uses to set COVID-19 vaccine payments. Additional details for providers about Medicare coding, payment and billing for monoclonal COVID-19 products and their administration are described in CMS’ Medicare Monoclonal Antibody COVID-19 Infusion Program Instruction.

Related News Articles

Headline
The House Ways and Means Subcommittees on Health and Oversight held a joint hearing today to discuss lessons learned, challenges and opportunities to improve…
Headline
The AHA today expressed support for the Medicare Mental Health Inpatient Equity Act, a bill that would eliminate the 190-day lifetime limit on inpatient…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The AHA July 8 wrote in opposition to the “Patient Access to Higher Quality Health Care Act” (H.R. 4002), which would repeal current law banning the creation…
Headline
The AHA July 3 released the Health Care Plan Accountability Update for the second quarter of 2025. The update covers the latest developments in Medicare…